Montaner et al. in a pilot, double-blind, randomized, multicenter clinical trial to study the efficacy of Simvastatin in the acute phase of ischemic stroke, evaluated the evolution of several inflammation markers [IL-6, IL-8, IL-10, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, C-reactive protein, sApo/Fas, tumor necrosis factor-alpha, E-selectin, L-selectin and nitrites + nitrates] and neurological outcome at baseline, day 1, 3, 5, 7 and 90. This evidence concerns the gene FAS and ischemic stroke.